|
| | | | | | | | | | | |
| Name | Indication | Economics | Class | Approved | IP | | | Price USD | 16.18 | |
| Prevacid/Takepron | Ulcer | 1 | PPI | | 11/1/2009 | | | Price JPY | 4470 | |
| Blopress (candesartan) | Hypertension | 1 | ARB | 1999 | | | | Shares | 1551.8086 | Q123 |
| Velcade (bortezomib) | Multiple Myeloma | JNJ | | | | | | MC | 6936584.442000001 | |
| Uloric (febuxostat) | Gout | 100%? | | | | | | Cash | 932561 | Q123 |
| Actos (pioglitazone) | Type 2 Diabetes | LLY 5% | PPAR | 1999 | 2011, Wockhardt | | | Debt | 5102147 | Q123 |
| Lupron/Leuplin | Prostate Cancer | ABT | LHRH agonist | | | | | EV | 11106170.442000002 | |
| Gattex | | | | | | | | | | |
| Protonix/Pantoloc/Controloc (pantoprazole) | GERD | | PPI | | | | | | | |
| Takecab (vonoprazan), fka TAK-438 | GERD | 1 | K-channel ant | | | | | | | |
| Entyvio (vedolizumab) | UC/Crohn's | 1 | a4b7 integrin | | | | | | | |
| Adcetris (brentuximab vedotin) | HL | SGEN | CD30 ADC | | | | | | | |
| Enbrel | Rheumatoid Arthrits | PFE/AMGN | TNF | | | | | CEO: Christophe Weber | | |
| Dexilant | Ulcer | 1 | PPI | 1/1/2009 | | | | CFO: Costa Saroukos | | |
| Vectibix (panitumumab) | mCRC | AMGN | VEGF mab | | | | | | | |
| Rozerem (ramelteon, fka TAK-375) | Insomnia | 1 | MT-1/MT-2 agonist | | | | | | | |
| Exkivity (mobocertinib) | NSCLC | | | | | | | | | |
| Livtencity (maribavir) | CMV | | | | | | | | | |
| Takhzyro (lanadelumab) | HAE | | | | | | | | | |
| Firazyr (icatibant) | HAE | | | | | | | | | |
| Iclusig (ponatinib) | CML/ALL | | | | | | | | | |
| Qdenga | Dengue | | | | | | | | | |
| Ninlaro (fka MLN 9708) (ixazomib) | Multiple Myeloma | 1 | Proteasome | | | | | | | |
| Trintellix/Lu AA21004 (vortioxetine) | Depression | LUN DC | SSRI | | | | | | | |
| Nesina (alogliptin) | Type 2 Diabetes | 90%, FURX 10% | DPP4 | | | | | | | |
| | | | | Phase | | | | | | |
| TAK-755 (apadamtase alfa/cinaxadamtase alfa) | cTTP | | ADAMTS13 | Filed | | | | 1500 sales people in Japan | | |
| TAK-279 | Psoriasis | SDGR | Tyk2 | III | | | | | | |
| TAK-861 | Narcolepsy | | orexin-2 agonist | | | | | | | |
| TAK-935 (soticlestat) | Dravet/LGS | | CH24H | | | | | | | |
| TAK-071 | Parkinson's | | M1 pam | | | | | | | |
| TAK-920/DNL919 | Alzheimer's | DNLI | TREM2 mab | I | | | | | | |
| TAK-113 (fruquintinib) | mCRC | | mCRC | | | | | | | |
| TAK-653/NBI-845 | Depression | NBIX | AMPA | II | | | | | | |
| TAK-041/NBI-846 | Depression | NBIX | GPR139 | II | | | | | | |
| TAK-925 (danavorexton) | postanesthesia recovery | 1 | orexin-2 agonist | I | | | | | | |
| TAK-341/MEDI1341 | MSA | AZN | alpha-synuclein mab | II | | | | | | |
| TAK-594/DNL593 | FTD | DNLI | progranulin | II | | | | | | |
| TAK-981 (subasumstat) | Oncology | 1 | SUMO | | | | | | | |
| TAK-573 (modakafusp) | Multiple Myeloma | | CD38 fusion | | | | | | | |
| TAK-007 | B cell lymphoma | | CD19 CAR-NK | | | | | | | |
| TAK-103 | Oncology | | Mesothelin CART | | | | | | | |
| TAK-102 | Oncology | | GPC3 CART | | | | | | | |
| TAK-676 | Oncology | | STING agonist | | | | | | | |
| fazirsiran (TAK-999) | Alpha-1 Antitypsin | ARWR | RNAi | III | | | | | | |
| TAK-141 (pabinafusp) | Hunter Syndrome | 1 | ERT | | | | | | | |
| | | | | | | | | | | |
| | | | | 1/4/2008: SYR-322 filing in the US. | | | | | | |
| | | | | 1/4/2008: File TAK390-MR. | | | | | | |
| | | | | May 2011: Announces Nycomed acquisition. | | | | | | |
| | | | | May 2011: Actos bladder cancer risk. | | | | | | |